When was MatTek founded?

MatTek was founded in 1985 and raised its 1st funding round 19 years after it was founded.

Where is MatTek located?

MatTek is headquartered in Ashland, United States. It is registered at Ashland, Massachusetts.

How many employees does MatTek have?

As of Apr 30, 2026, the latest employee count at MatTek is 65.

Is MatTek a funded company?

MatTek is a funded company, having raised an undisclosed amount across 28 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2004.

When was the latest funding round of MatTek?

MatTek's latest funding was a $***** Grant (prize money) round on 2020, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $802M in funding in 2026 to date.

Where does MatTek rank among its competitors?

MatTek ranks 254th amongst 1973 active competitors, of which 457 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of MatTek?

MatTek's top competitors include Synthego, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

MatTek - 2026 Company Profile, Funding & Competitors

Company Details

Innovating in vitro science with human-relevant 3D tissue models and services. They are dedicated to advancing in vitro science through innovative, human-relevant technologies. They offer lab-grown human epithelial tissues, living, metabolically active 3D tissue models that provide greater insight into clinical outcomes. Their expertise in cell isolation and expansion has created a large and diverse inventory of primary cells from native donor tissue. They provide cultureware, reagents, and supporting materials for enhanced tissue characterization. Their products and services support research in dermal, immune cell, intestinal, ocular, oral mucosal, respiratory, and vaginal applications. They offer toxicity and safety assessment services, including cytotoxicity-hepatotoxicity screening, and in vitro services like blood-brain barrier permeability assays and cancer drug screening. They provide digital pathology services, immuno-oncology tissue analysis, and image analysis services. They are committed to ethical, human-relevant in vitro science, offering innovative life science technologies.

Website: www.mattek.com/
Social
Email ID: *****@mattek.com
Registered Address: Ashland, Massachusetts

Key Metrics

Founded Year

1985

Location

Ashland, United States

Stage

Acquired

Latest Funding Round

Grant (prize money), 2020, $*****

Investors

HHS

Ranked

254^th among 1973 active competitors

Employee Count

65 as on Apr 30, 2026

Similar Companies

Synthego & 2686 more

Exit Details

Acquired by Sartorius (Apr 10, 2025)

View MatTek's full profile

MatTek is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MATS COMPANY s.r.o. CIN: 07390262 , Czech Republic, Active	Aug 22, 2018	-	-
MA company, s.r.o. CIN: 17053269 , Czech Republic, Active	Apr 14, 2022	-	-
Mattek Corporation CIN: 42877744 , United States, Active	Dec 26, 999	-	67 (As on Dec 31, 2022)	-

MatTek got acquired by Sartorius on Apr 10, 2025.

Click here to take a look at MatTek's acquisition in detail

MatTek has raised funding over 28 rounds. Its first funding round was on 2004. Its latest funding round was a Grant (prize money) round on 2020 for $*****. 1 investor participated in its latest round. MatTek has 1 institutional investor.

Here is the list of recent funding rounds of MatTek:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2020	9905	Grant (prize money)	5215	5234	8050	3994
2019	8891	Grant (prize money)	5672	8778	4947	HHS
2014	7058	Grant (prize money)	5374	3290	2984	HHS

Access funding benchmarks and valuations. Sign up today!

View details of MatTek's funding rounds and investors

MatTek's employee count trend

MatTek has 65 employees as of Apr 26. Here is MatTek's employee count trend over the years:

Uncover MatTek's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MatTek include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of MatTek, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Sino Biopharmaceutical, Orbimed & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, Verition Fund Management ... & 14 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$346M	Maverick Ventures, Polaris Partners & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
254th	MatTek 1985, Ashland (United States), Acquired	Innovating in vitro science with human-relevant 3D tissue models and services	-	HHS	41/100